RVPG
DNA icon

Relative Value Partners Group’s Ginkgo Bioworks DNA Stock Holding History

Relative Value Partners Group’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$10.2K Buy
+766
New +$22.9K ﹤0.01% 320

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Relative Value Partners Group's DNA Position: Q2 2024 in Review

Relative Value Partners Group opened a new position in Ginkgo Bioworks (DNA) in Q2 2024: 766 shares worth $10.2K. The stake represents ﹤0.01% of the portfolio and ranks #320 among its holdings.

313 funds tracked by Wall St. Rank hold DNA as of Q2 2024.

  • Relative Value Partners Group held 766 shares of Ginkgo Bioworks worth $10.2K as of Q2 2024.
  • Ginkgo Bioworks was a new Relative Value Partners Group position in Q2 2024.
  • Ginkgo Bioworks made up ﹤0.01% of Relative Value Partners Group's portfolio in Q2 2024, its #320 holding.
  • 313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2024.

Based on Relative Value Partners Group's 13F filing for Q2 2024, filed 12 Jul 2024.